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Abstract 
 
Formation of arterio-venous-fistulae (AVF) may exacerbate cardiac failure in the ever increasing, elderly population 
on haemodialysis. Brain Natriuretic Peptide (BNP) may prove a useful marker of cardiac failure in this population. 
We aimed to determine effect of creation of an AVF and flow in AVF on BNP levels. Ten patients undergoing 
primary formation of an upper limb autologous AVF (pre-dialysis), were recruited. Serum BNP (pg/ml) and flow in 
AVF (cm3/s) were documented pre-operatively, and then 2, 6 and 12 weeks post-operatively. The relationship 
between flow and BNP levels was assessed. Ten patients (6 male), mean age of 66yrs were recruited. Five patients 
had a radio-cephalic and 5 had a brachio-cephalic AVF formed. There was no correlation between BNP levels and 
flow within the AVF (r=0.34, p=0.28) at any time point. There was a general trend towards increased flow in the 
AVF over time, with only the change between flow at 2-weeks and 3-months postoperatively reaching significance, 
p=0.043. There was a general trend for BNP to fall over time in the postoperative period, with no significant change 
between the postoperative sampling time points. BNP levels do not correlate with flow across an AVF. 
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Introduction 
 
Creation of an arteriovenous fistula (AVF) for chronic 
haemodialysis therapy provides convenient access to 
the circulation in patients with end-stage renal disease 
(1). High output cardiac failure is a recognized 
complication of AVF (2-4). The reported incidence of 
this complication has been low, with less than 1% of 
patients requiring ligation of an AV fistula for this. 
However, the population of patients undergoing renal 
replacement therapy has changed dramatically in 
recent years, and more than half of all patients starting 
haemodialysis are greater than 60 years of age (5). 
Consequently, a significant larger proportion of 
patients present with cardiac dysfunction at the time of 
requiring dialysis. Furthermore, in this population of 
patients, symptoms of cardiac failure could be pre-
existing and may be in part similar to the symptoms of 
renal failure. Therefore, insidious onset of these 
symptoms may not raise the same degree of alarm in 
clinicians.  
 
B-type natriuretic peptide (BNP) is one of four cardiac 
natriuretic peptides. It is synthesized as pre-proBNP 
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mainly in the ventricular endocardium in response to 
ventricular stretch and pressure overload. The levels of 
BNP strongly correlate with left ventricular (LV) 
chamber size and LV end diastolic pressures (6). Pre-
proBNP is enzymatically cleaved to form proBNP and is 
subsequently released in the form of hormonally active 
BNP and inactive N-terminal pro-BNP (NT-proBNP).  
 
The major role of natriuretic peptides is to induce 
natriuresis through their action on renal 
haemodynamics and tubular function. Other functions 
of natriuretic peptides include vasodilation, decrease in 
sympathetic outflow as well as inhibition of 
vasopressin and aldosterone release (7-9).  The net 
result of natriuretic peptide release is reduction in 
cardiac preload. BNP is a very powerful tool in the 
diagnosis of heart failure (10-12).  
 
Serum BNP is known to be elevated in patients with 
renal failure by several orders of magnitude (7), this has 
been considered to limit its value as a diagnostic tool 
in the management of such patients if cardiac failure is 
suspected. In addition to this, renal dialysis has a 
significant impact on the serum BNP levels with a 
significant reduction in levels following 
haemodialysis. However, there is accumulating 
evidence to suggest that serum BNP levels have a 
prognostic value in patients with end stage renal 
failure (11, 13-16). Chronic volume overload in end 
stage renal disease predisposes patients to left 
ventricular hypertrophy which may be exacerbated by 
formation of an AV fistula.  
 
We aimed to assess serum BNP levels pre and post 
formation of an AVF in order to determine the 
feasibility of utilizing serum BNP for predicting 
cardiac outcome following AV fistula formation. 
Furthermore, we aimed to determine the blood flow 
across the newly formed fistula to see if this impacts 
on BNP levels. If a change in serum BNP is detected 
following the formation of an AV fistula we aim to 
follow up with a study to assess the role of BNP as a 
predictor of medium term survival in patients 
following the formation of AV fistula and investigate 
serial changes in cardiac performance before and after 
the formation of AV fistula. 
 
Materials and Methods 
 
Ethical approval was granted from Tayside Research 
Ethics Committee. Ten patients were prospectively 
recruited prior to the formation of their AV fistula, 
following informed consent. All ten patients were 
referred to a vascular surgeon with a specialist interest 
in renal access, for pre-emptive primary formation of 
an autologous AVF (i.e. none of the patients were on 
dialysis prior to the formation of the AV) for chronic 
haemodialysis as advised in recent guidelines (17, 18). 
All patients underwent duplex imaging of the upper 
limb veins and arteries. The unit’s preference was to 
form distal AVF prior to central AVF, non dominant 
over dominant limb, depending on time requirement 
for commencement of dialysis or presence of central 
venous dialysis line, preferably using vein >3mm and 
artery greater > 2mm with biphasic flow. The veins 
were assessed for central stenosis/occlusion, with 
venography performed in situations of doubt. AVF 
formation was performed under either local 
anaesthesia or regional block with or without sedation. 
The anastomosis was fashioned in an end to side 
fashion using either 6/0 or 7/0 prolene depending on 
calibre of vessels.  
 
Information collected included: age; sex; operation; 
American Society of Anesthesiologists score (ASA); 
pre-operative ischemic heart disease (as defined by 
Lee et al  (19); congestive heart failure (as defined by 
Swedberg et al (20)); New York Heart Association 
score (NYHA); diabetes mellitus; cerebro-vascular 
disease; Chronic Obstructive Pulmonary Disease 
(COPD; operative duration; pre-operative serum 
creatine (µmol/l); pre-operative estimated glomerular 
filtration rate (eGFR). All patients were followed up 
for a minimum of one year or until death.  
 
Patient inclusion criteria include: Age > 18 years; Age 
< 85 years. 
 
Patient exclusion criteria include: Pre-existing AV 
fistula; Already established on dialysis; Diagnosis of 
severe cardiac failure; Life expectancy < 12 months; 
Unable to perform 6-minute walking performance test 
due to physical disability 
 
BNP Analysis 
 
Venous blood was sampled for BNP on the same day, 
but prior to surgery and then at regular intervals in the 
post-operative period (2 weeks, 6 weeks, 3 months and 
6 months post-operative). The sample was collected in 
spray coated, K2-EDTA tubes (Becton Dickinson, BD 
Vacutainer®, Oxford, United Kingdom) and 
immediately centrifuged and stored at -70°C until 
analysis as a batch at the end of patient recruitment. 
BNP levels were measured by a standard 
commercially available radioimmunoassay kit 
(Peninsula Laboratories, Merseyside, UK), by an 
experienced biochemist blinded to patient outcome. 
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Fistula Assessment 
 
Duplex surveillance of the AVF was performed at 
regular intervals in the peri-operative period (2 weeks, 
6 weeks, 3 months and 6 months post-operative), after 
20 minutes rest to exclude exertional effects, 
documenting time averaged velocity and diameter in 
the venous limb of the AVF and AVF patency. Flow 
(cm3/s) within the AVF was calculated using the 
following formula: time averaged velocity in venous 
limb x (venous diameter/2)2 X π at same site. The 
average of three separate recording was taken. Clinical 
evaluation was assessed in terms of 6-minute walking 
test, according to the guidelines of the American 
Thoracic Society (21) and NYHA status at the same 
pre and post-operative follow up appointments as BNP 
sampling.  
 
Statistics 
Test of association used the ANOVA and Chi-squared 
statistic. Spearman rank correlation was performed to 
assess relationship between flow in AVF and serum 
BNP, with paired sample T test performed to compare 
data before and after AVF formation. Analysis was 
performed on the Statistical Package for Social 
Sciences (Statistical Package for the Social Sciences 
V17.1, Chicago, USA). A p-value of less than 0.05 
denotes significance. 
 
Results 
 
Ten patients (6 male) undergoing primary formation of 
AVF for chronic haemodialysis were recruited 
following informed consent, with a mean age of 66 
years (range 48-82), with patient characteristics 
displayed in Table 1. Five of the AVF were autologous 
radio-cephalic fistulae, the remaining five were 
autologous brachio-cephalic fistulae. Median operative 
time for RC AVF was 90 minutes (range 35 -120), and 
for BC AVF 60 minutes (range 45 -75), p=0.14. One 
patient died five days post formation of her AVF of a 
myocardial infarction, having the second highest pre-
operative BNP (393 pg/ml). One fistula occluded 
during the follow up period on day 63 post formation 
(brachio-cephalic fistula). All other fistulae matured 
successfully. Irrespective of timing of BNP sampling 
and assessment of AVF flow, there was no correlation 
between BNP levels and flow within the AVF (r=0.34, 
p=0.28), figure 1. On comparing change in mean flow 
over time (Figure 2), there was a general trend towards 
increased flow in the AVF over time, with only change 
between flow at 2 weeks and 3 months postoperative 
reaching significance, p=0.043. On comparing change 
in mean serum BNP over time (Figure 3), there was a 
general trend for serum BNP to fall over time in the 
postoperative period, with no significant change   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Correlation between serum BNP and flow 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Mean change in flow (cm3/sec) over time (+/- 
S.E.M.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Mean change in serum BNP (pg/ml) over time (+/- 
S.E.M.)  
 
between the postoperative sampling time points. Pre-
operative median distance walked during the 6 minute 
walking test was 180m. Following AVF formation, 
performance on this test deteriorated gradually over a 
3 month period with median difference in distance 
walked reduced by 5m, 10m and 24m at 2, 6 and 12 
weeks respectively, although this did not reach 
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significance. Pre-operatively patients fell equally into 
Class 1 and 2 of NYHA Classification (50:50). There 
was no noticeable change in NYHA class during the 
follow up period despite there being a downward trend 
in the 6 min walk test. 
 
Discussion 
 
BNP has been shown to be a marker of left ventricular 
dysfunction in patients established on long term 
dialysis therapy (22, 23), and an effective marker of 
left ventricular dysfunction and predictive of 
congestive cardiac failure in patients with known 
chronic renal impairment not yet established on 
dialysis (1). BNP levels do not undergo marked 
fluctuation in patients on established dialysis 
compared with other natriuretic peptides, and best 
correlated with left ventricular function rather than 
volume status (24). In a study on 164 patients on 
established haemodialysis, Naganuma et al determined 
that BNP levels taken post haemodialysis were 
associated with volume overload, even more so in 
those patients with cardiovascular disease (14). With 
regards to the two main forms of BNP, the hormonally 
active BNP and the inactive NT-proBNP, despite BNP 
and NT-proBNP levels being inversely proportional to 
GFR, BNP may be a better marker of cardiac function 
in those with renal impairment compared to NT-
proBNP, as NT-proBNP clearance is reduced in 
correlation with decreased eGFR (25). In contrast to 
this, Anwaruddin and colleagues (26) in an analysis of 
nearly 600 patients in the PRIDE study, found that 
although NT-proBNP was inversely related to eGFR, 
this relationship was not purely due to reduced 
clearance but more likely reflecting underlying cardiac 
disease and increased plasma volume. In a small study 
of patients with chronic kidney disease stage 5 on 
stable chronic haemodialysis, David and co-workers 
showed that NT-proBNP levels sampled post dialysis, 
were predictive of volume overload, even in those 
patients with normal cardiac function (based on 
echocardiography and indices of hydration status), and 
as such was a marker of left ventricular dysfunction in 
patients on stable haemodialysis (27). 
 
Few studies have looked at the effect of AVF 
formation on serum BNP levels, let alone correlated 
these levels with flow through the AVF. Ori et al, 
investigating a group of 10 patients pre and two weeks 
post formation of AVF, discovered that in the short 
term the formation of an AVF leads to fluid overload 
which is off set by reduced peripheral vascular 
resistance (28). Jin et al reported on a case of recurrent 
high output cardiac failure with preserved cardiac 
ejection fraction in a patient with an aneurysmal AVF 
and markedly raised BNP (29). In this case, flow 
through the AVF was calculated at over 25% of the 
cardiac output (29). In our study, we noted the 
formation of an AVF resulted in a non-significant 
decrease in BNP over the post-operative period, whilst 
flow rates in the AVF increased over time, with no 
significant correlation between flow in the AVF and 
serum BNP levels. In contrast, two small studies 
assessing the effect of AVF formation on cardiac 
function (5, 30), showed an increase in BNP in the 
post-operative period. Malik et al, studying the effects 
of AVF creation (6 weeks and 6 months post AVF 
formation) in 35 patients already established on 
dialysis via a central venous catheter, found the 
creation of an AVF with ‘normal’ flow (<1500ml/min, 
>300ml/min) lead to a significant increase in BNP, 
which was related to flow across the AVF only at the 6 
week time point. Similar flow rates were found 
between this study and ours. They concluded that the 
increase of BNP probably mirrors worsening of 
clinically silent heart failure. Iwashima and colleagues 
studied the effects of AVF formation on ANP, BNP 
and cardiac function (as determined by 
echocardiography) in the first two weeks post AVF 
formation in 16 patients not established on dialysis (5). 
They found that the formation of an AVF for chronic 
haemodialysis had significant effects on both cardiac 
systolic and diastolic function.  Serum BNP levels 
increased in the post-operative period, related to left 
ventricular dysfunction (5). 
 
A limitation of our study, as well as others, is the small 
number of patients included and the subsequent death of 
one patient and occlusion of another AVF may have had 
an adverse impact. Another possible factor that may 
bear influence on BNP levels, are prescribed cardiac 
medications used in the treatment of cardiac failure. 
Irrespective of this, we would expect that in those 
patients with documented cardiac failure requiring 
medications, the formation of an AVF would have an 
adverse effect on the cardiac function and subsequently 
lead to an increased BNP level. We plan to undertake 
further evaluation of the patients in our study once they 
have been established and are stable on long term 
haemodialysis, to assess the impact of commencement 
of haemodialysis on flow and BNP levels.  
 
The creation of autologous arterio-venous fistulae in 
patients not established on haemodialysis, did not lead 
to increased serum BNP levels. Furthermore flow 
across the arterio-venous fistula did not correlate with 
serum BNP levels. 
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